Power to the Patients

Brandon Li

0,0 (0)
Scienze biologiche
Ogni settimana

Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com

13 mag

How Neuroplasticity Is Shaping the Next Generation of Psychiatric Medicines

Dr. Aaron Koenig, Chief Medical Officer at Delix Therapeutics, sheds light on a new class of medicines designed to promote neuroplasticity without the hallucinogenic effects associated with psychedelics. On this episode of Power to the Patients, Koenig explains to host Brandon Li how neuroplasticogens could provide scalable treatments for depression and other serious brain disorders, why separating plasticity from psychedelic experiences matters for clinical development, and how emerging biomarkers such as qEEG may help measure brain changes in patients. The conversation spans scientific rationale, clinical challenges, and long term potential of plasticity-based therapeutics in psychiatry and neurology.

34 min
30 apr

70% Remission for Postpartum Depression? The Psychedelic Breakthrough

Postpartum depression treatment advances with psychedelic therapy. Greg Mayes of Reunion Neuroscience discusses luvesilocin drug development. This episode explores how shorter-acting psilocybin analogs offer new hope for mothers. Greg highlights the success of the RECONNECT study and the path to FDA breakthrough designation.

36 min
15 apr

Why Psychiatry Is Finally Breaking Free From Dopamine

In this episode of Power to the Patients, host Brandon Li sits down with Ken Kramer, PhD, Vice President and Head of Neuropsychiatry Medical Affairs at Bristol Myers Squibb, to explore why psychiatry has lagged behind other therapeutic areas and what’s finally changing. Kramer explains how decades of reliance on dopamine-based antipsychotics shaped treatment, and why new mechanisms like muscarinic agonism are opening the door to safer, more effective options for patients with schizophrenia.

29 min
1 apr

Precision Medicine Got Kidney Disease Wrong—Until Now

Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform.

42 min
18 mar

Why Dr. Ken Sharlin Believes Most Neurological Diseases Are Reversible

In this episode of Power to the Patients, host Brandon Li sits down with Dr. Ken Sharlin, neurologist, researcher, and clinical trial investigator, to explore how precision medicine, functional neurology, and emerging technologies are redefining what’s possible in neurodegenerative disease care. Dr. Sharlin challenges the traditional disease-centered model and shares why restoring biological balance - rather than simply managing symptoms, may unlock new pathways for prevention, reversal, and personalized treatment in conditions like MS, Alzheimer’s, and Parkinson’s.

38 min
11 mar

Why Serotonin Isn’t Outdated, Our Thinking Is

In this episode of Power to the Patients, host Brandon Li sits down with Dr. Jacob Jacobsen, neuroscientist and CEO of Evecxia Therapeutics, to challenge some of psychiatry’s most deeply held assumptions. Dr. Seld explains why clinical novelty, not mechanistic novelty, is what truly matters to patients, and how amplifying serotonin synthesis may offer a safer, more scalable path forward for treating depression and OCD.

41 min
25 feb

Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian

In this episode of Power to the Patients, host Brandon Li sits down with Dr. Lara Shirikjian, Medical Director at CenExel, to explore why operational excellence, not just innovation, drives progress in psychiatric drug development. Drawing on more than two decades of experience in schizophrenia and CNS research, Dr. Shirikjian explains how protocol mastery, direct sponsor communication, and community trust are essential to running high-performing research sites and advancing meaningful psychiatric treatments.

40 min
18 feb

Turning Pain Into Progress: How Sonia Prashar Built a Mission Around Mental Health

In this episode of Power to the Patients, Brandon Li and Sonia Prashar, Founder and CEO of AIM Trials, sit down to discuss how hybrid and decentralized clinical trial models are reshaping mental health research. Sonia shares how her personal experience with postpartum depression inspired a mission to reduce patient burden, expand access, and improve data quality, while challenging stigma and outdated research assumptions along the way.

34 min

Elenco completo (54)

Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com

Creatore

Brandon Li
Anni di attività

2023 - 2026
Puntate

54
Classificazione

Contenuti adatti a tutti
Copyright

© 315762
Sito web del podcast

Power to the Patients
Fornitore